These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15375314)

  • 61. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells.
    Benimetskaya L; Miller P; Benimetsky S; Maciaszek A; Guga P; Beaucage SL; Wilk A; Grajkowski A; Halperin AL; Stein CA
    Mol Pharmacol; 2001 Dec; 60(6):1296-307. PubMed ID: 11723237
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bcl-2 antisense therapy in hematologic malignancies.
    Chanan-Khan A
    Curr Opin Oncol; 2004 Nov; 16(6):581-5. PubMed ID: 15627020
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Oligonucleotide therapeutics for human leukaemia.
    Gewirtz AM
    Ciba Found Symp; 1997; 209():169-91; discussion 191-4. PubMed ID: 9383576
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Tumor regression by combination antisense therapy against Plk1 and Bcl-2.
    Elez R; Piiper A; Kronenberger B; Kock M; Brendel M; Hermann E; Pliquett U; Neumann E; Zeuzem S
    Oncogene; 2003 Jan; 22(1):69-80. PubMed ID: 12527909
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents.
    Tortora G; Caputo R; Damiano V; Bianco R; Pepe S; Pomatico G; Bianco AR; Jiang Z; Agrawal S; Ciardiello F
    Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):141-5. PubMed ID: 9593054
    [No Abstract]   [Full Text] [Related]  

  • 66. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; Pepe S; Bianco AR; Agrawal S; Mendelsohn J; Tortora G
    J Natl Cancer Inst; 1998 Jul; 90(14):1087-94. PubMed ID: 9672257
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study.
    Rudin CM; Marshall JL; Huang CH; Kindler HL; Zhang C; Kumar D; Gokhale PC; Steinberg J; Wanaski S; Kasid UN; Ratain MJ
    Clin Cancer Res; 2004 Nov; 10(21):7244-51. PubMed ID: 15534098
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
    Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
    Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antisense approaches in prostate cancer.
    Chi KN; Gleave ME
    Expert Opin Biol Ther; 2004 Jun; 4(6):927-36. PubMed ID: 15174974
    [TBL] [Abstract][Full Text] [Related]  

  • 70. 2'-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo.
    Prakash TP; Johnston JF; Graham MJ; Condon TP; Manoharan M
    Nucleic Acids Res; 2004; 32(2):828-33. PubMed ID: 14762210
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Antisense approaches enter the clinic.
    Khuri FR; Kurie JM
    Clin Cancer Res; 2000 May; 6(5):1607-10. PubMed ID: 10815875
    [No Abstract]   [Full Text] [Related]  

  • 72. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
    Klasa RJ; Gillum AM; Klem RE; Frankel SR
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Protamine-fragment peptides fused to an SV40 nuclear localization signal deliver oligonucleotides that produce antisense effects in prostate and bladder carcinoma cells.
    Benimetskaya L; Guzzo-Pernell N; Liu ST; Lai JC; Miller P; Stein CA
    Bioconjug Chem; 2002; 13(2):177-87. PubMed ID: 11906253
    [TBL] [Abstract][Full Text] [Related]  

  • 74. New agents in the treatment of CLL.
    O'Brien S
    Hematology Am Soc Hematol Educ Program; 2008; ():457-64. PubMed ID: 19074126
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Therapeutic intervention in glomerulonephritis by oligonucleotides.
    Kashihara N; Maeshima Y; Makino H
    Exp Nephrol; 1997; 5(2):126-31. PubMed ID: 9108994
    [No Abstract]   [Full Text] [Related]  

  • 76. The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression.
    Barradas M; Monjas A; Diaz-Meco MT; Serrano M; Moscat J
    EMBO J; 1999 Nov; 18(22):6362-9. PubMed ID: 10562548
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Use of antisense oligonucleotides for therapy. Manipulation of apoptosis inhibitors for destruction of lung cancer cells.
    Leech SH; Olie RA; Zangemeister-Wittke U
    Methods Mol Med; 2003; 75():655-70. PubMed ID: 12407770
    [No Abstract]   [Full Text] [Related]  

  • 78. From bench top to bedside.
    Barinaga M
    Science; 1997 Nov; 278(5340):1036-9. PubMed ID: 9381201
    [No Abstract]   [Full Text] [Related]  

  • 79. Technology evaluation: LErafAON, NeoPharm.
    Moreira JN; Simões S
    Curr Opin Mol Ther; 2003 Oct; 5(5):547-52. PubMed ID: 14601525
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
    Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
    J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.